Morgans, A. K., Touya, M., El-Chaar, N. N., Elsouda, D., Ramaswamy, K., Adejumo, K. L., . . . Freedland, S. J. (2/10/2025 Supplement5). Impact of physicians' awareness of prostate-specific antigen doubling time (PSADT) on treatment (Tx) decisions in high-risk (HR) biochemically recurrent (BCR) prostate cancer (PC). Journal of Clinical Oncology, 43, 354-479.
Copiado correctamente al portapapeles
Error al copiar al portapapeles
Cita Chicago Style (17a ed.)
Morgans, Alicia K., et al. "Impact of Physicians' Awareness of Prostate-specific Antigen Doubling Time (PSADT) on Treatment (Tx) Decisions in High-risk (HR) Biochemically Recurrent (BCR) Prostate Cancer (PC)."
Journal of Clinical Oncology 43 (2/10/2025 Supplement5): 354-479.
Copiado correctamente al portapapeles
Error al copiar al portapapeles
Cita MLA (9a ed.)
Morgans, Alicia K., et al. "Impact of Physicians' Awareness of Prostate-specific Antigen Doubling Time (PSADT) on Treatment (Tx) Decisions in High-risk (HR) Biochemically Recurrent (BCR) Prostate Cancer (PC)."
Journal of Clinical Oncology, vol. 43, 2/10/2025 Supplement5, pp. 354-479.
Copiado correctamente al portapapeles
Error al copiar al portapapeles
Precaución: Estas citas no son 100% exactas.